Last reviewed · How we verify
NCT03480737
Brain Stimulation for Working Memory Deficits in Adolescents With ADHD
NA trial testing Magstim Super Rapid2 stimulator, 10 Hz condition in ADHD With Working Memory Deficits in 14 participants. Completed in 30 March 2023.
30 March 2023
Quick facts
| Lead sponsor | Bradley Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 1 November 2019 |
| Primary completion | 30 March 2023 |
| Estimated completion | 30 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Magstim Super Rapid2 stimulator, 10 Hz condition
- Magstim Super Rapid2 stimulator, Sham condition
- Magstim Super Rapid2 stimulator, iTBS condition
Conditions studied
- ADHD With Working Memory Deficits — all drugs for ADHD With Working Memory Deficits →
Sponsor
Bradley Hospital
Who can join
Adults 13 to 17, any sex, with ADHD With Working Memory Deficits. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Working memory (WM) is the foundational cognitive control process of holding information 'in mind' to execute goal-directed behaviors. WM deficits are an established component of ADHD. Despite being one of the strongest predictors of poor clinical and functional outcomes in pediatric mental health, there remains a dearth of available treatments for WM deficits. Non-invasive brain stimulation hold tremendous promise in transforming psychiatry, as it takes a "brain-first" approach to treatment. The dorsolateral prefrontal cortex (DLPFC) is the known structural foundation of WM, and the interaction between slow and fast brain waves (i.e., "theta-gamma coupling \[TGC\]") is a neural, functional foundation of WM. Thus, the DLPFC and TGC are potential brain-based targets for the modulation of WM with brain stimulation. Intermittent theta burst stimulation (iTBS) is a novel paradigm that applies a three-minute dose of stimulation to the DLPFC at an intensity that directly mimics TGC dynamics. The objective of this study is to test whether iTBS can enhance dysfunctional brain activity that causes working memory deficits. iTBS will be tested compared to standard or traditional transcranial magnetic stimulation (TMS), called 10 Hz TMS. It will also be compared to sham or fake TMS. Each participant receives a single session of each of these types of TMS. EEG will record neural activity during a working memory test immediately before and after each TMS session. If this study shows TMS can enhance dysfunctional brain activity, the next step will be to conduct a clinical trial to test if TMS can lead to a sustained, positive effect on working memory deficits.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03480737
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bradley Hospital trials
Trials by the same sponsor.
- NCT06549491 — A Sleep Intervention for Preschoolers in Foster Care · NA · not yet recruiting
- NCT06885047 — Culturally Centered CBT Protocol for Suicidal Behaviors Among Youth in Mexico City · NA · not yet recruiting
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting
- NCT07379853 — Interactive E-Learning for Therapist Training in Exposure Therapy · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03480737 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bradley Hospital
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03480737.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing